Bulle, Switzerland
UCB is investing EU250 million to expand its facilities in Bulle, Switzerland. A microbial manufacturing unit will be built to produce a treatment for rheumatoid arthritis and Crohn's disease. The expansion is slated for completion in 2015. UCB is also constructing a bioprocessing pilot plant in Belgium.
